4.87
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SLS Giù?
Forum
Previsione
Frazionamento azionario
Sellas Life Sciences Group Inc Borsa (SLS) Ultime notizie
SLS stock kicks off week in green: CEO flags role in EU biotech policy talks that could impact drug approvals - MSN
SLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvals - Stocktwits
SLS stock slips after-hours as cancer pipeline silence frustrates retail — China licensing fight now in spotlight - MSN
SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results - Stocktwits
SLS stock gains momentum: NVDA, MSFT investor loads up ahead of AML trial milestone trigger - MSN
Sellas Life Sciences draws significant retail buzz as traders eye REGAL phase 3 catalyst – SLS stock soars 15% - MSN
SLS News | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
SLS stock sparks retail buzz ahead of AACR presentation on experimental cancer therapy - MSN
SLS stock jumps premarket: US investor Dagco boosts stake by 78% ahead of fresh cancer drug data reveal - MSN
SLS Forecast, Price Target & Analyst Ratings | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
SLS stock jumps overnight: ‘potent’ AML drug data ahead of cancer summit fuels fresh momentum - MSN
SELLAS Life Sciences Group (SLS) price target increased by 15.38% to 10.20 - MSN
SELLAS LIFE SCIENCES GROUP, INC. (SLS) - MSN
SLS stock rises premarket ahead of cancer summit this month – investors eye phase 3 AML trial milestone - MSN
SELLAS Life Sciences Group (SLS) price target increased by 26.83% to 8.84 - MSN
SLS Stock Gains Momentum: NVDA, MSFT Investor Loads Up Ahead Of AML Trial Milestone Trigger - Stocktwits
SLS stock jumps overnight: CEO doubles down on ‘steadfast’ confidence in AML drug and pushes for 20M share plan approval - MSN
SLS stock rallies ahead of AML trial readout — 'Pharma Bro' Martin Shkreli says he's still 'very bearish,' predicts drug will fail - MSN
SLS Stock Holds Support As Cash Pile Fuels Biotech Bounce - StocksToTrade
Wall Street analysts think SELLAS Life Sciences Group, Inc. (SLS) could surge 66.09%: Read this before placing a bet - MSN
SELLAS Life Sciences falls for fourth straight session — what’s driving the sell-off? - MSN
Sellas Life Sciences Stock In Spotlight After Institutional Investor Exercises Existing Warrants - MSN
SLS Stock Jumps Overnight: CEO Doubles Down On ‘Steadfast’ Confidence In AML Drug And Pushes For 20M Share Plan Approval - Stocktwits
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):